[Prevention and treatment of postoperative complications of hepatic echinococcosis].
The paper presents the outcomes of surgical treatment in 117 patients with complicated liver echinococciasis in the past 9 years. Hepatic function and immunity, their pre- and postoperative changes in the combined use of essentiale and T-activin were studied. It has been found that the functional status of the liver, its detoxifying function in particular, largely impairs and immunosuppression develops in patients with complicated liver echinococciasis. The postoperative combined use of essentiale and T-activin led to the normalization of hepatic function and immunity. The combined treatment reduced the incidence of postoperative complications from 34.83 to 17.2%, such as acute hepatic failure, suppuration of a wound and a residual cavity, isolated abdominal abscesses, pleurisy, and pneumonia.
Akhmedov
R M
RM
Ochilov
U B
UB
Mirkhodzhaev
I A
IA
Komilov
T S
TS
Makliev
B Iu
BIu
D018784:Abdominal Abscess / Q000188:drug therapy / Q000517:prevention & control; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D004444:Echinococcosis, Hepatic / Q000276:immunology / Q000601:surgery*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D017093:Liver Failure / Q000188:drug therapy / Q000517:prevention & control; D008111:Liver Function Tests; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000627:therapeutic use*; D010998:Pleurisy / Q000188:drug therapy / Q000517:prevention & control; D011014:Pneumonia / Q000188:drug therapy / Q000517:prevention & control; D011183:Postoperative Complications / Q000188:drug therapy* / Q000517:prevention & control; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000517:prevention & control; D013949:Thymus Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D010455:Peptides; D010713:Phosphatidylcholines; D013949:Thymus Extracts; C011246:essential 303 forte; C036191:T-activin